{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T12:56:16Z","timestamp":1771937776106,"version":"3.50.1"},"reference-count":38,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,3,1]],"date-time":"2012-03-01T00:00:00Z","timestamp":1330560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.1016\/j.pnpbp.2011.10.009","type":"journal-article","created":{"date-parts":[[2011,10,20]],"date-time":"2011-10-20T14:40:45Z","timestamp":1319121645000},"page":"251-257","source":"Crossref","is-referenced-by-count":24,"title":["Long-term efficacy and safety of gabapentin enacarbil in Japanese restless legs syndrome patients"],"prefix":"10.1016","volume":"36","author":[{"given":"Yuichi","family":"Inoue","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naohisa","family":"Uchimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Kuroda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Hirata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobutaka","family":"Hattori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pnpbp.2011.10.009_rf0180","series-title":"Restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health","author":"Allen","year":"2003"},{"key":"10.1016\/j.pnpbp.2011.10.009_bb0005_2","doi-asserted-by":"crossref","unstructured":"Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology: a report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med 2003;4:101\u201319.","DOI":"10.1016\/S1389-9457(03)00010-8"},{"key":"10.1016\/j.pnpbp.2011.10.009_bb0010","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1001\/archinte.165.11.1286","article-title":"Restless legs syndrome prevalence and impact: REST general population study","volume":"165","author":"Allen","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.pnpbp.2011.10.009_bb0015","series-title":"Diagnostic and Coding Manual","article-title":"The International Classification of Sleep Disorders","author":"American Academy of Sleep Medicine","year":"2005"},{"key":"10.1016\/j.pnpbp.2011.10.009_bb0020","doi-asserted-by":"crossref","first-page":"512","DOI":"10.4065\/mcp.2009.0700","article-title":"Long-term maintenance treatment of restless legs syndrome with gabapentin enacarbil: a randomized controlled study","volume":"85","author":"Bogan","year":"2010","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.pnpbp.2011.10.009_bb0025","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1124\/jpet.104.067934","article-title":"XP13512 [(+\/\u2212)-1-([(alpha-isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: I. design, synthesis, enzymatic conversion to gabapentin, and transport by intestinal solute transporters","volume":"311","author":"Cundy","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pnpbp.2011.10.009_bb0030","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1177\/0091270008322909","article-title":"Clinical pharmacokinetics of XP13512, a novel transported prodrug of gabapentin","volume":"48","author":"Cundy","year":"2008","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.pnpbp.2011.10.009_bb0035","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.sleep.2010.07.007","article-title":"Restless legs syndrome: understanding its consequences and the need for better treatment","volume":"11","author":"Earley","year":"2010","journal-title":"Sleep Med"},{"key":"10.1016\/j.pnpbp.2011.10.009_bb0040","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/WNF.0b013e3182087d48","article-title":"A 52-week study of gabapentin enacarbil in restless legs syndrome","volume":"34","author":"Ellenbogen","year":"2011","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.pnpbp.2011.10.009_bb0045","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1093\/brain\/awm244","article-title":"Where dopamine meets opioids: a meta-analysis of the placebo effect in restless legs syndrome treatment studies","volume":"131","author":"Fulda","year":"2008","journal-title":"Brain"},{"key":"10.1016\/j.pnpbp.2011.10.009_bb0055","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1212\/WNL.59.10.1573","article-title":"Treatment of restless legs syndrome with gabapentin: a double-blind, cross-over study","volume":"59","author":"Garcia-Borreguero","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.pnpbp.2011.10.009_bb0185","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.sleep.2006.09.009","article-title":"A 52-week open-label study of the long-term safety of ropinirole in patients with restless legs syndrome","volume":"8","author":"Garcia-Borreguero","year":"2007","journal-title":"Sleep Med"},{"key":"10.1016\/j.pnpbp.2011.10.009_bb0060","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1185\/030079906X132442","article-title":"Efficacy and tolerability of ropinirole in patients with restless legs syndrome and a baseline IRLS total score \u2265 24 points\u2014data from the ropinirole clinical trial programme","volume":"22","author":"Giorgi","year":"2006","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.pnpbp.2011.10.009_bb0065","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1159\/000072882","article-title":"Gabapentin versus ropinirole in the treatment of idiopathic restless legs syndrome","volume":"48","author":"Happe","year":"2003","journal-title":"Neuropsychobiology"},{"key":"10.1016\/j.pnpbp.2011.10.009_bb0070","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1007\/s00415-009-5299-8","article-title":"Progressive development of augmentation during long-term treatment with levodopa in restless legs syndrome: results of a prospective multi-center study","volume":"257","author":"H\u00f6gl","year":"2010","journal-title":"J Neurol"},{"key":"10.1016\/j.pnpbp.2011.10.009_bb0075","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jns.2010.04.003","article-title":"Long-term open-label study of pramipexole in patients with primary restless legs syndrome","volume":"294","author":"Inoue","year":"2010","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.pnpbp.2011.10.009_bb0080","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s11136-006-9142-8","article-title":"Burden of restless legs syndrome on health-related quality of life","volume":"16","author":"Kushida","year":"2007","journal-title":"Qual Life Res"},{"key":"10.1016\/j.pnpbp.2011.10.009_bb0085","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1212\/01.wnl.0000341770.91926.cc","article-title":"Randomized, double-blind, placebo-controlled study of XP13512\/GSK1838262 in patients with RLS","volume":"72","author":"Kushida","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.pnpbp.2011.10.009_bb0090","first-page":"91","article-title":"Gabapentin enacarbil, a gabapentin prodrug for the treatment of the neurological symptoms associated with disorders such as restless legs syndrome","volume":"10","author":"Merlino","year":"2009","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1016\/j.pnpbp.2011.10.009_bb0095","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1081\/JDI-120039823","article-title":"Gabapentin versus levodopa for the treatment of restless legs syndrome in hemodialysis patients: an open-label study","volume":"26","author":"Micozkadioglu","year":"2004","journal-title":"Ren Fail"},{"key":"10.1016\/j.pnpbp.2011.10.009_bb0100","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1111\/j.1468-1331.2006.01459.x","article-title":"Long-term treatment with pramipexole in restless legs syndrome","volume":"13","author":"Montplaisir","year":"2006","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.pnpbp.2011.10.009_bb0105","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1002\/mds.21050","article-title":"Ropinirole is effective in the long-term management of restless legs syndrome: a randomized controlled trial","volume":"21","author":"Montplaisir","year":"2006","journal-title":"Mov Disord"},{"key":"10.1016\/j.pnpbp.2011.10.009_bb0110","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1479-8425.2008.00349.x","article-title":"Email-based epidemiological surveys on restless legs syndrome in Japan","volume":"6","author":"Nomura","year":"2008","journal-title":"Sleep Biol Rhythm"},{"key":"10.1016\/j.pnpbp.2011.10.009_bb0115","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1002\/mds.22274","article-title":"Prevalence of restless legs syndrome in a rural community in Japan","volume":"23","author":"Nomura","year":"2008","journal-title":"Mov Disord"},{"key":"10.1016\/j.pnpbp.2011.10.009_bb0120","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.sleep.2008.04.012","article-title":"One year open-label safety and efficacy trial with rotigotine transdermal patch in moderate to severe idiopathic restless legs syndrome","volume":"9","author":"Oertel","year":"2008","journal-title":"Sleep Med"},{"key":"10.1016\/j.pnpbp.2011.10.009_bb0125","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0022-3999(02)00443-9","article-title":"Prevalence of restless legs syndrome and periodic limb movement disorder in the general population","volume":"53","author":"Ohayon","year":"2002","journal-title":"J Psychosom Res"},{"key":"10.1016\/j.pnpbp.2011.10.009_bb0130","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.sleep.2007.12.004","article-title":"Open-label study of the long-term efficacy and safety of pramipexole in patients with Restless Legs Syndrome (extension of the PRELUDE study)","volume":"9","author":"Partinen","year":"2008","journal-title":"Sleep Med"},{"key":"10.1016\/j.pnpbp.2011.10.009_bb0135","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1212\/WNL.54.5.1064","article-title":"Prevalence and risk factors of RLS in an elderly population: the MEMO study. Memory and Morbidity in Augsburg Elderly","volume":"54","author":"Rothdach","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.pnpbp.2011.10.009_rf0205","series-title":"Medical Advisory Board of the Restless Legs Syndrome Foundation","author":"Silber","year":"2004"},{"key":"10.1016\/j.pnpbp.2011.10.009_bb0140_2","doi-asserted-by":"crossref","unstructured":"An algorithm for the management of restless legs syndrome. Mayo Clin Proc 2004;79:916\u201322.","DOI":"10.4065\/79.7.916"},{"key":"10.1016\/j.pnpbp.2011.10.009_bb0145","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1053\/ajkd.2001.25202","article-title":"A crossover study of gabapentin in treatment of restless legs syndrome among hemodialysis patients","volume":"38","author":"Thorp","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.pnpbp.2011.10.009_bb0160","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nrneurol.2010.55","article-title":"Restless legs syndrome: pathophysiology, clinical presentation and management","volume":"6","author":"Trenkwalder","year":"2010","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.pnpbp.2011.10.009_bb0155","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1002\/mds.22254","article-title":"Treatment of restless legs syndrome: an evidence-based review and implications for clinical practice","volume":"23","author":"Trenkwalder","year":"2008","journal-title":"Mov Disord"},{"key":"10.1016\/j.pnpbp.2011.10.009_bb0150","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S1474-4422(08)70112-1","article-title":"Efficacy of rotigotine for treatment of moderate-to-severe restless legs syndrome: a randomised, double-blind, placebo-controlled trial","volume":"7","author":"Trenkwalder","year":"2008","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.pnpbp.2011.10.009_bb0165","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/WNF.0b013e3181b3ab16","article-title":"Gabapentin enacarbil in restless legs syndrome: a phase 2b, 2-week, randomized, double-blind, placebo-controlled trial","volume":"32","author":"Walters","year":"2009","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.pnpbp.2011.10.009_bb0175","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.sleep.2003.07.005","article-title":"Augmentation and tolerance with long-term pramipexole treatment of restless legs syndrome (RLS)","volume":"5","author":"Winkelman","year":"2004","journal-title":"Sleep Med"},{"key":"10.1016\/j.pnpbp.2011.10.009_bb0170","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.sleep.2006.01.004","article-title":"Prevalence and correlates of restless legs syndrome symptoms in the Wisconsin Sleep Cohort","volume":"7","author":"Winkelman","year":"2006","journal-title":"Sleep Med"},{"key":"10.1016\/j.pnpbp.2011.10.009_bb0180","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1212\/01.wnl.0000231513.23919.a1","article-title":"Efficacy and safety of pramipexole in restless legs syndrome","volume":"67","author":"Winkelman","year":"2006","journal-title":"Neurology"}],"container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S027858461100306X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S027858461100306X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,18]],"date-time":"2019-06-18T02:49:42Z","timestamp":1560826182000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S027858461100306X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["S027858461100306X"],"URL":"https:\/\/doi.org\/10.1016\/j.pnpbp.2011.10.009","relation":{},"ISSN":["0278-5846"],"issn-type":[{"value":"0278-5846","type":"print"}],"subject":[],"published":{"date-parts":[[2012,3]]}}}